Pediatric Rheumatology Online
Journal
Vol 2, No. 2 2004
http://www.pedrheumonlinejournal.org
Quality of life in children with
systemic lupus erythematosus: The search for appropriate measurement tools.
L. Nandini Moorthy1, Melanie J. Harrison2, Peterson, Margaret2, Karen B. Onel2, Thomas J.A. Lehman2
Affiliations:
1.
Robert Wood Johnson Medical School-UMDNJ,
2.
Hospital For Special Surgery,
Keywords: Quality of life, Systemic lupus
erythematosus, Children, Physical function, proxy respondents
Contact:
L. Nandini Moorthy,
MD MS
Robert Wood Johnson
Medical School-UMDNJ, Dept. of Pediatrics, MEB 396 A,
Phone: (732) 235
9378 (Work)
Email: LNMoorthy@mac.com;
Abstract
Systemic
lupus erythematosus (SLE) in children is a chronic multi-system disease with wide
ranging effects on their quality of life (QOL).
While SLE’s impact on different arenas of life and well-being has been
extensively examined in the adult population, its effect on children has not
received adequate attention. This article briefly discusses the
multidimensional aspect of QOL, the biopsychosocial implications of SLE,
factors complicating QOL measurement in the affected population, and the
different generic and disease-specific scales used for measuring QOL and
related constructs, thereby highlighting the need for a SLE-specific pediatric
QOL instrument.
Introduction
There is no single
definition for quality of life (QOL), as it is a global, dynamic and personal
construct, encompassing physical, psychological and social domains [1-3]. Health-related QOL (HRQOL), distinct from QOL
and health status, is defined as “optimum levels of mental, physical, role and
social functioning, including relationships, and perceptions of health,
fitness, life satisfaction and well-being,” incorporating the “assessment of
patient’s satisfaction with treatment, outcome and health status and with
future prospects” [2, 4]. Although its relevance to children has been
questioned, the revised International Classification of Impairments,
Disabilities, and Handicaps published by the World Health Organization provides
a new framework delineating parameters of health and disability as body structure
and function, activities, participation, and environmental factors [5].
QOL, as impacted by
health or disease becomes especially relevant in children with chronic
illnesses such as systemic lupus erythematosus (SLE). In children, SLE is associated with
significant morbidity consequential to their disease and treatment, and
comprises a wide-ranging spectrum of physical, psychosocial and economic
implications. Impact of specific organ
involvement, especially the skin, renal and central nervous systems, requires
in-depth examination. There is
sufficient evidence from research on adults, that SLE affects multiple
dimensions (including psychological) of QOL, thus emphasizing the importance of
determining a reliable instrument to measure QOL in children with SLE [6-21].
Despite recognizing the considerable effect of SLE on children and their
families, very few pediatric studies explore the widespread impact of SLE on
QOL or the ideal methods of measuring the same.
Difficulties encountered in measuring
QOL in pediatric SLE
SLE’s chronic,
episodic and unpredictable course, its extremely varied presentations within
and between patients, associated psychosocial factors, and patient/family
expectations complicate the measurement of QOL in children. The use of a generic
versus a disease-specific instrument for evaluating a specific disease with
wide-ranging effects such as SLE poses a great dilemma [22].
Generic instruments
developed for use within a general population or for patients with a variety of
diseases may be limited to assessing the overall aspects of all diseases and
may lack responsiveness to clinical changes [23-25]. As such, these instruments may not adequately
capture and measure the extent of the impact on a particular organ system
especially in case of central nervous or renal involvement, where cognitive
function, psychiatric, financial and logistic effects require consideration.
Self-esteem and body image may be affected in children with widespread skin
rash, cushingoid features, alopecia and/or fatigue affecting their peer
relationships. Conversely,
disease-specific instruments may lack sensitivity for the particular condition
and may not adequately measure QOL in children with mild SLE, those in remission,
or those with more than one chronic condition [26]. Despite the restrictions that generic and
disease-specific instruments impose within the context of a multisystemic
disease such as SLE, their combined use may allow measurement of the global and
SLE-specific impact on QOL in children.
QOL measures are
developed with a particular focus and/or for a specific population and
therefore, should not be expected to adequately assess all aspects of health
and/or wellbeing in another population [27]. For example, in pediatric
rheumatology, outcome measures are primarily focused on impact of physical
disability on various domains of well-being because the majority of the
children have juvenile idiopathic arthritis (JIA). Although physical function
is an important
domain affected in
SLE, a true measure of SLE-related QOL would have to take into
consideration other domains of well-being, and adequately assess the impact of
renal and central nervous system involvement, as well as the effect of
medication.
Children’s
evolving needs and expectations is another impediment. Several QOL scales---adapted from the adult
scales---may not account for children’s developmental stages that affect
cognitive function, autonomy, body image and recall [22]. Given that small numerical differences in
children’s age translate into important psychosocial changes of great clinical
significance, it is crucial to develop age-adjusted formats for children that
consider their changing cognitive skills [28].
Since QOL is a
uniquely personal construct, it is best for children to evaluate their own
QOL. However, the limitations in using
children as their own respondents include unreliable or invalid results based
on their varying degrees of long-term perspective, memory, age, health, mood,
and communication skills [29].
Therefore, the parents, as proxy respondents may be useful in these circumstances. However, they may be
influenced by their personal expectations and experiences, as well as their own
health and mental status [29]. Moreover,
parents' perception of the child’s QOL, often based on areas that they deem
important and of value to their children, greatly motivates seeking health care
for the child, resulting in a selection bias [30]. Studies examining parent-child concordance
and have found that the level of agreement varies and is dependent on the
domain studied, and also patients’ and parents’ physical and mental health
status [31-33]. In order to maximize
accuracy and to explore the determinants of parent-child concordance, an argument
can be made for using parallel parent and child versions for assessing QOL in chronic,
ever-changing, potentially life-threatening and deforming multi-systemic
illnesses such as SLE.
Assessment of QOL and health status in
pediatric rheumatic diseases
The majority of
pediatric studies use descriptive QOL measures, which explore various domains
of QOL, instead of utilities or preference-based measures, which quantitatively
estimate individual preferences of children [34, 35]. A description of some of
the QOL measures will provide insight into the various domains that comprise
QOL and enable assessment of measures in pediatric rheumatic disease. Since results with utility scales have been
shown to vary widely in children with
musculoskeletal diseases, this account will focus on descriptive measures
[36]. An attempt is made to categorize
scales commonly used in pediatric rheumatic diseases into generic,
disease/system-specific measures, and generic measures with disease/system-specific
modules.
Generic measures
Short-Form-36
(SF-36) and Short Form-20 (SF-20)
The
SF-36 and SF 20 are reliable and valid health status measures widely used in
clinical studies of both healthy and sick adults, including those rheumatic
diseases, and are sometimes used in older children [6-8, 13, 19, 21, 42-46].
The SF-36 assesses domains of physical functioning, role limitations due to
physical health and emotional problems, bodily pain, social functioning,
general mental health covering psychological distress and well-being, vitality,
energy or fatigue, and general health perceptions, areas that are relevant in
all healthy and sick individuals. The major limitation of studies using SF-36
or SF-20 is that they claim to be measuring QOL when they are actually
measuring health status. Additionally, in the case of children, they exhibit ceiling
effects and do not show adequate variability and discriminant validity
[47]. Therefore, a cautious
review of studies using these instruments is critical.
Child
Health Questionnaire (CHQ)
A widely used
global health status measure in children is the CHQ, which was derived along
the lines of the SF-36, and has domains adapted for children [48]. Although there are parent-reports (for
children over 5 years) and child-reports (over 10 years), they are not entirely
parallel. The CHQ is valid, reliable and
has been found to be responsive to clinical changes in children with JIA [48,
49]. It has been used widely as a health
status measure and is being adapted cross-culturally in different countries
[48, 50-53]. Although the CHQ has domains (physical functioning, role/social –
emotional, role/social – behavioral, role/social – physical, bodily pain,
general behavior, mental health, self esteem, general health perceptions,
change in health, parental impact – emotional, parental impact – time, family
activities, family cohesion) that would be relevant for all children including
those with SLE, further testing is necessary to determine if the scale captures
the SLE-specific impact on QOL. The
major limitations are the lack of parallel versions, lack of validity for
children under 5 years of age and lack of child-report for ages under 10 years.
Childhood
Health Assessment Questionnaire (CHAQ)
The CHAQ, the most
extensively administered measure of physical function in children with
rheumatic diseases, is modified from the Health Assessment Questionnaire (HAQ)
[54-57]. The domains of the CHAQ are
similar to that of the adult HAQ, which in addition to disability and discomfort,
evaluates drug side effects, death and dollar costs. The CHAQ consists of
brief, easily administered, parallel child-
(8-19 years) and parent-reports (2-19 years), with the chief areas of
focus being disability and discomfort. The 30 items on the questionnaire
estimate disability in areas of dressing and grooming, arising, eating,
walking, hygiene, reach, grip, and activities.
Although found to be reliable and valid, studies are mixed in terms of
its responsiveness to clinical change [54, 58, 59]. The CHAQ is a widely employed, functional
assessment tool in diverse studies of children with arthritis and is being
cross-culturally adapted and translated into different languages [50]. The minimal clinically important change to
enable prospective follow-up of physical function in children with JIA has been
determined for the CHAQ scores [60].
CHAQ is also valid, reliable, and sensitive to clinical change in
children with idiopathic inflammatory myositis [61]. The CHAQ may be useful in
children with SLE with physical disability such as avascular necrosis, severe
arthritis or fatigue.
Other
questionnaires
The EuroQOL, a
generic health utility index widely used in adult studies has demonstrated
validity in assessing children with JIA [62-64]. The TNO AZL Children's Quality
of Life questionnaire (TACQOL) is a generic QOL instrument in children aged
6-15 years limited by lack of validity in older and younger children [29]. This questionnaire assesses the domains of pain
and symptoms, basic motor functioning, autonomy, cognitive functioning, social
functioning, global positive emotional functioning, global negative and
emotional functioning, many of which are affected in children with chronic
diseases such as SLE. Quality of My
Life Visual Analog Scale has been used for measuring the overall QOL in
children, but there are very few studies published using this instrument [4].
Disease/System-specific
measures
Although most of
the instruments described in this section are more relevant to children with
arthritis, they may be relevant in children with SLE with severe fatigue,
musculoskeletal involvement including arthritis or avascular necrosis where
physical function is compromised.
Juvenile Arthritis Quality of Life Questionnaire (JAQQ)
The JAQQ is a valid
and responsive disease-specific instrument assessing physical and psychosocial
function in children with juvenile arthritis, including spondyloarthropathies
[65-68]. Despite its strong psychometric
properties, including content validity, the JAQQ lacks the ability to
discriminate between groups [69].
Childhood
Arthritis Health Profile (CAHP)
The CAHP was
designed as a parent-report to assess the overall physical and psychosocial
health status of children over 13 years with arthritis through the domains of
physical functional status, psychosocial functioning, behavior, general health
perceptions, family functioning and impact of disease [70, 71]. General health
status is evaluated by the CHQ, and the disease-specific impact is assessed by
a focused section on juvenile arthritis [48, 72]. Despite the desirable combination of global
and disease-specific aspects of rheumatic illness and relevant domains for
children, the CAHP is not widely used as there are too few studies published
using the measure, there is no parallel child-report, and it lacks validity in
children under 13 years of age.
Juvenile Arthritis
Functional Assessment Scale (JAFAS), Juvenile Arthritis Functional Assessment
Report (JAFAR) and Juvenile Arthritis Functional Status Index (JASI)
The JAFAS
and the JAFAR are valid and reliable scales of physical function in children
above 7 years of age [73, 74]. JAFAS has
not gained popularity because of its length, the need for trained health
professional and standardized equipment, lack of established responsiveness,
and lack of validity in younger children.
The JAFAR child- and parent-reports has been found to be responsive and
used in several clinical studies of children with JIA, limited only because of
lack of validity for younger children [74-77].
The JASI is a reliable and valid measure of activities of daily living
and functional mobility in children with arthritis less than 8 years of age
[78, 79]. Despite good psychometric
properties and a patient-specific part, it is not widely used due to increased
time of administration, lack of established responsiveness and the lack of
validity in children greater than 8 years of age.
Generic measures with disease/system-specific modules
Pediatric QOL Inventory (PedsQL)
The PedsQL-Generic
module (version 4.0), a descriptive measure in the form of a brief, easily
administered questionnaire, is designed to assess QOL in healthy and sick
children and can be used to compare different populations. It is both a reliable and valid measure of
QOL in children between ages 2-18 years in different pediatric settings [28,
37-39]. The initial PedsQL (version 1.0)
was developed from a pediatric cancer database and has been modified since [28,
40, 41]. The most recent version,
PedsQL4.0, which measures the essential domains as specified by the WHO, has
both child- and parent-reports with separate language-adjusted formats for
different ages 5-7, 8-12 and 13-18 years.
The parent-report has an additional questionnaire for toddlers aged
2-4. The generic core module consists of
four domains: physical, emotional, social, and school functioning, which are
scored to yield total, physical, and psychosocial summary scores.
The
most current version of the PedsQL-Rheumatology module (3.0), formatted similar
to the Generic module, is comprised of five domains: pain and hurt, daily
activities, treatment, worry, and communication [39]. Only the domain scores are reported and not
the total mean score, which limits its use in pediatric rheumatic disease
studies, where sample sizes are often small.
The PedsQL should be suitable for the measurement of QOL in children
with all rheumatic diseases including SLE since it appears to take into account
both global and specific domains impacted by a chronic rheumatic disease.
General
limitations of current measures and proposals for future development
The various questionnaires
described above have been used widely in studies of children with rheumatic
diseases; they have different limiting features when considered in the context
of pediatric SLE. First, many of these
instruments are heavily weighted towards determining the impact of arthritis,
which is not the single major complaint in children with SLE. Secondly, these instruments may not
adequately capture all the relevant domains in pediatric SLE unless used in
conjunction with other measures [80].
Thirdly, not all the instruments are valid, reliable and responsive over
time to clinical changes. Lastly, some
instruments do not have parallel self- and parent-reports and they are not
applicable to all pediatric age-groups.
Those that do not have parent-reports, limit their use to children who
are older and are well enough to complete them.
The majority of the children with SLE are adolescents, but it is
preferable to have a measure that will be able to assess younger children as
well. Instruments that lack self-report versions may not accurately measure the
child’s QOL and require parents to be used as proxies. Some measures are not validated for the
complete pediatric age group, and therefore cannot be widely used for data
collection where patient population spans a wide spectrum of ages. Certain measures have both child and parent
versions but the versions are not in parallel, thus limiting accurate
estimation of concordance between child- and proxy-respondents.
A generic QOL tool
could be valuable in comparing children with SLE to other disease/healthy
groups. A SLE-specific tool that would
assess impact on QOL would be very useful especially if used in conjunction
with tests validated for assessing disease activity, damage and
neuropsychiatric status [81-83]. Until
there are SLE-specific QOL scales available, a combination of previously
validated scales may be used for pediatric SLE.
Recently
conducted qualitative research in children with SLE and their families has yielded
important information regarding critical domains affecting QOL in children with
SLE [84]. An
adequate measure QOL in pediatric SLE should have domains that are based on
patient’s attitudes and expectations in order to incorporate the
patient-perceived global and disease-specific impact of SLE, so that the health
domains measured would be relevant for them.
Qualitative research
would be the next step to confirm the validity and completeness of the health
domains. Additionally,
it should be brief, easy to administer, with complete scoring coupled with
having parallel child and parent versions with language-adjusted formats for
different age groups. Finally, it should
have validity and reliability across a wide age-range, which will facilitate
clinical comparisons and long-term prospective outcome studies in this
population. It is not realistic to develop a single tool that fulfills all the
criteria mentioned above. However, the
development of a SLE-specific tool that measures at least most of the domains
is critical for optimizing care in these children.
Conclusion
Although many of the
instruments developed to assess QOL and related constructs such as health status
and physical function have demonstrated utility in specific population groups,
inherent problems complicate the accurate and comprehensive assessment of QOL
in children with SLE. Some of the
problems of current instruments include emphasis on other diseases, specific age
group limits, non-availability of corresponding child or parent version, length
and difficulty of administration. Such
limitations compromise the measurement of QOL, thus restricting the effort to
fully meet the growing challenges and needs of children with SLE. The need for a disease-specific instrument
specifically applicable for children with SLE becomes particularly evident in
this context. Understanding issues
critical to QOL and developing effective measures of disease impact can help to
mitigate distress secondary to medical and psychosocial impact of SLE in
children and their families.
References
1. World Health Organization, Health Promotion
Glossary. 1998, World Health Organization,
2. Bowling, A., Health-Related Quality of Life:
Conceptual Meaning, Use and Measurement, in Measuring disease: A review of
disease-specific quality of life measurement scales. 2001, Open University
Press: Buckingham,
3. Calman, K., Quality of life in cancer
patients--an hypothesis. Journal of Medical Ethics., 1984. 10(3): p. 124-7.
4. Feldman, B., et al., Distinction of quality
of life, health related quality of life, and health status in children referred
for rheumatologic care. [see c
comments.]. Journal of Rheumatology, 2000. 21(1): p. 226-33.
5. Simeonsson RJ, Lollar D, Hollowell J, Adams
M, Revision of the International Classification of Impairments, Disabilities,
and Handicaps Developmental issues. Journal of Clinical Epidemiology, 2000. 53(2):
p. 113-124.
6. Perez-Cuevas JB, Formiga F, Garcia-Carrasco
M, Ramos M, Lara C, Rojas-Rodriguez J., A quality of life study in women with
systemic lupus erythematosus and its relation to disease activity[Spanish].
Anales de Medicina Interna, 1999. 16(9): p. 457-60.
7. Gilboe IM, Kvien TK, Husby G., Health status
in systemic lupus erythematosus compared to rheumatoid arthritis and healthy
controls. Journal of Rheumatology, 1999. 26(8): p. 1694-700.
8. Sutcliffe N, Clarke AE, Levinton C, Frost C,
Gordon C, Isenberg DA., Associates of health status in patients with systemic
lupus erythematosus. Journal of Rheumatology, 1999. 26(11): p. 2352-6.
9. Dobkin PL, Da Costa D, Dritsa
M,, et al., Quality of life in systemic lupus erythematosus patients during
more and less active disease states: differential contributors to mental and
physical health. Arthritis Care & Research, 1999. 12(6): p. 401-10.
10. Burckhardt CS, Archenholtz B, Bjelle A.,
Quality of life of women with systemic lupus erythematosus: a comparison with
women with rheumatoid arthritis. Journal of Rheumatology, 1993. 20(6): p.
977-81.
11. Hanly JG., Disease activity, cumulative
damage and quality of life in systemic lupus erythematosus: results of a
cross-sectional study. Lupus, 1997. 6(3): p. 243-7.
12. Stoll T, Gordon C, Seifert B, et al.,
Consistency and validity of patient administered assessment of quality of life
by the MOS SF-36; its association with disease activity and damage in patients
with systemic lupus erythematosus. Journal of Rheumatology, 1997. 24(8): p.
1608-14.
13. Fortin PR, Abrahamowicz M, Neville C, et al.,
Impact of disease activity and cumulative damage on the health of lupus
patients. Lupus, 1998. 7(2): p. 101-7.
14. Lash, A., Quality of life in systemic lupus erythematosus.
Source Applied Nursing Research, 1988. 11(3): p. 130-7.
15. Hochberg MC, Sutton JD., Physical disability
and psychosocial dysfunction in systemic lupus erythematosus. Journal of
Rheumatology, 1988. 15(6): p. 959-64.
16. Dobkin PL, Fortin PR, Joseph L, Esdaile JM,
Danoff DS, Clarke AE., Psychosocial contributors to mental and physical health
in patients with systemic lupus erythematosus. Arthritis Care & Research,
1998. 11(1): p. 23-31.
17. Maeshima E, Yamada Y, Mune M, Yukawa S.,
Subjective happiness and psychological condition in SLE. [Japanese]. Ryumachi,
1996. 36(6): p. 830-6.
18. Liang MH, Rogers M, Larson M, et al., The
psychosocial impact of systemic lupus erythematosus and rheumatoid arthritis.
Arthritis & Rheumatism, 1984. 27(1).
19. Thumboo J,
20. Wang C,
21. Karlson EW, Daltroy LH, Lew RA et al., The
relationship of socioeconomic status, race, and modifiable risk factors to
outcomes in patients with systemic lupus erythematosus. Arthritis &
Rheumatism., 1997. 40(1): p. 47-56.
22. Eiser C, Morse R., Quality-of-life Measures
in Chronic Diseases of childhood, in Health Technology Assessment. 2001,
Department of Psychology,
23. Patrick DL, Deyo RA., Generic and
disease-specific measures in assessing health status and quality of life. Med
Care, 1989. 27(3): p. S127-S232.
24. Juniper EF, Guyatt GH, Feeny DH, Griffith
LE., Minimum skills required by children to complete health-related quality of
life instruments for asthma: comparison of measurement properties. Eur Respir
J, 1997. 10(10): p. 2285-94.
25. Patrick DL, Erikckson P., Health status and
health policy. 1993,
26. Fitzpatrick R, Davey C, Buxton MJ, Jones DR.,
Evaluating patient-based outcome measures for use in clinical trials. Health
Technol Assess, 1998. 2(14).
27. Bowling A., What things are important in people's
lives? A survey of the public's judgements to inform scales of health related
quality of life. Social Science & Medicine, 1995. 41(10): p. 1447-62.
28. Varni, JW, Seid M, Rode CA.,
The PedsQL: measurement model for the pediatric quality of life inventory. Med
Care, 1999. 37(2): p. 126-39.
29. Vogels T, Verrips GH,
Verloove-Vanhorick SP, et al., Measuring health-related quality of life in
children: the development of the TACQOL parent form. Quality of Life Research.,
1998. 7(5): p. 457-65.
30. Varni JW, Seid M, Kurtin PS.,
Pediatric Health-Related Quality of LIfe Measurement Technology: A Guide for
Health Care Decision Makers. JCOM, 1999. 6(4): p. 33-40.
31. Loonen HJ, Derkx BHF, Koopman
HM, Heymans HSA., Are parents able to rate the symptoms and quality of life of
their offsprings with IBD? Inflammatory Bowel disease, 2002. 8(4): p. 270-276.
32. Brunner HI, Klein-Gitelman
MS, Miller MJ. et al., Are parents good proxy reporters for children with
chronic musculoskeletal disprders (MSKD)? ACR 65th Annual Meeting,
33. Eiser C, Morse R,. Can
Parents rate their child's health-related Quality of life? Results of a
systematic review. Quality of Life Research, 2001. 10: p. 347-357.
34. Siderowf A, Ravina B, Glick
HA., Preference-based quality-of-life in patients with Parkinson's disease.
Neurology 2002 Jul 9;59(1):103-7., 2002. 9(59): p. 103-7.
35. Wu AW, Jacobson KD, Frick DL,
et al., Validity and responsiveness of the euroqol as a measure of
health-related quality of life in people enrolled in an AIDS clinical trial.
Quality of Life Research, 2002. 11(3): p. 273-82.
36. Brunner HI, Maker D,
Grundland B, et al., Preference-based
measurement of health-related quality of life (HRQL) in children with chronic
musculoskeletal disorders (MSKDs). Medical Decision Making, 2003. 23(4): p.
314-22.
37. Varni JW, Seid M, Kurtin PS.
PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory
version 4.0 generic core scales in healthy and patient populations. Med Care,
2001. 39(8): p. 800-12.
38. Varni JW, Burwinkle TM, Katz
ER, Meeske K,
39. Varni JW, Seid M, Smith et al., The PedsQL in pediatric
rheumatology: reliability, validity, and responsiveness of the Pediatric
Quality of Life Inventory Generic Core Scales and Rheumatology Module.
Arthritis & Rheumatism, 2002. 46(3): p. 714-25.
40. Varni JW, Rode CA,
Seid M, Katz ER, Friedman-Bender A, Quiggins DJ., The
Pediatric Cancer Quality of Life Inventory-32 (PCQL-32). II. Feasibility and
range of measurement. Journal of Behavioral Medicine, 1999. 22(4): p. 397-406.
41. Varni JW, Katz ER, Seid M,
Quiggins DJ, Friedman-Bender A, Castro CM.,
The Pediatric Cancer Quality of Life Inventory (PCQL). I. Instrument
development, descriptive statistics, and cross-informant variance. Journal of
Behavioral Medicine., 1998. 21(2): p. 179-204.
42. Ware JE, Sherbourne CD., The
MOS 36-item Short-Form Health Survey (SF-36) I. Conceptual framework and item
selection. Med Care, 1992. 30: p. 473-483.
43. Ware JE, Rand Corporation., General Health
Status and Quality of life, in Measuring Health - A Guide To Rating Scales and
Questionnaires, I.M.a.C. Newell, Editor. 1996,
44. Ware JE, Snow KK, Kosinski M
et al., SF-36 Health Survey: manual and interpretation guide. 1993,
45. Vu TV, Escalante A., A
comparison of the quality of life of patients with systemic lupus erythematosus
with and without endstage renal disease. Journal of Rheumatology.
26(12):2595-601, 1999 Dec., 1999. 26(12): p. 2595-601.
46. Stoll T, Kauer Y, Buchi S,
Klaghofer R, Sensky T, Villiger PM., Prediction of depression in systemic lupus
erythematosus patients using SF-36 Mental Health scores. Rheumatology, 2001.
40(6): p. 695-8.
47. Vitale MG,
48. Landgraf JM,
49. Selvaag AM, Flato B, Lien G,
Sorskaar D, Vinje O, Forre, O., Measuring health status in early juvenile
idiopathic arthritis: determinants and responsiveness of the child health
questionnaire . Journal of Rheumatology, 2003. 30(7): p. 1602-10.
50. Ruperto N, Ravelli A, Pistorio A, et al.,
Cross-cultural adaptation and psychometric evaluation of the Childhood Health
Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) in 32
countries. Review of the general methodology. Clinical & Experimental
Rheumatology., 2001. 19 (4 Suppl 23): p. S1-9.
51. Landgraf JM,
52. Landgraf JM., Vice President Scientific
Services, HealthAct, Measuring Pediatric Outcomes in Applied Clinical Settings:
An update about the Child Health Questionnaires (CHQ). Quality of Life News
Letter, MAPI Research Institute, 1999: p. 5-6.
53. Ruperto N, Ravelli A, Pistorio A, et al., The
Italian version of the Childhood Health Assessment Questionnaire (CHAQ) and the
Child Health Questionnaire (CHQ). Clinical & Experimental Rheumatology,
2001. 19(4 suppl 23): p. S91-5.
54. Singh G, Athreya BH, Fries
JF, Goldsmith DP., Measurement of health status in children with juvenile
rheumatoid arthritis. Arthritis and Rheumatism, 1994. 37: p. 1761-1769.
55. Fries J., The assessment of disability: from
first to future principles. Br J Rheumatol, 1983. 22(Suppl): p. 48-58.
56. Fries JF, Spitz P, Kraines
RG, Holman HR., Measurement of patient outcome in arthritis. Arthritis &
Rheumatism, 1980. 23: p. 137-145.
57. Ramey DR, Raynaud JP, Fries
J., The Health Assessment Questionnaire 1992: status and review. Arthritis Care
& Research, 1992. 5: p. 119-129.
58. Singh G, Bown B, Athreya B., Functional
status in juvenile rheumatoid arthritis: senstivity to change of the Childhood
Health Assessment Questionnaire. Arthritis
Rheum, 1991. 34: p. S81.
59. Ruperto N, Ravelli A,
Migliavacca D, et al., Responsiveness of
clinical measures in children with oligoarticular juvenile chronic arthritis.
Journal of Rheumatology, 1999. 26(8): p. 1827-30.
60. Dempster H, Porepa M, Young N, Feldman BM.,
The clinical meaning of functional outcome scores in children with juvenile
arthritis. Arthritis & Rheumatism., 2001. 44(8): p. 1768-74.
61. Huber AM, Hicks JE, Lachenbruch PA, et al.,
Juvenile Dermatomyositis Disease Activity Collaborative Study Group.,
Validation of the Childhood Health Assessment Questionnaire in the juvenile
idiopathic myopathies. Juvenile Dermatomyositis Disease Activity Collaborative
Study Group. Journal of Rheumatology, 2001. 28(5): p. 1106-11.
62. Brooks R., EuroQol: the current state of
play. [Review] [32 refs]. Health Policy, 1996. 37(1): p. 53-72.
63. Dawson J, Fitzpatrick R,
Frost S, Gundle R, McLardy-Smith P, Murray D., Evidence for the validity of a
patient-based instrument for assessment of outcome after revision hip
replacement. Journal of Bone & Joint Surgery - British Volume, 2001. 83(8):
p. 1125-9.
64. Glick HA, Shpall EJ ,LeMaistre
CF, et al., Empirical criteria for the selection of quality-of-life instruments
for the evaluation of peripheral blood progenitor cell transplantation.
International Journal of Technology Assessment in Health Care, 1998. 14(3): p.
419-30.
65. Duffy CM, Arsenault L, Duffy
KN, Paquin JD, Strawczynski H.., The Juvenile Arthritis Quality of Life
Questionnaire--development of a new responsive index for juvenile rheumatoid
arthritis and juvenile spondyloarthritides. Journal of Rheumatology, 1997. 24(4):
p. 738-46.
66. Duffy CM, Arsenault L,
Watanabe-Duffy KN, et al., Validity and sensitivity to change of the
Juvenile Arthritis Quality of Life
Questionnaire (JAQQ). Arthritis & Rheumatism, 1993. 37: p. S144.
67. Duffy CM, Arsenault L,
Watanabe-Duffy KN, et al., Relative sensitivity to change of the Juvenile
Quality of Life Questionnaire following a new treatment. Arthritis &
Rheumatism, 1994. 37: p. S196.
68. Duffy CM, Arsenault L, Watanabe-Duffy KN, et
al., Relative sensitivity to change of the Juvenile Arthritis Quality of Life
Questionnaires on sequential followup. Arthritis & Rheumatism, 1995. 38: p.
S178.
69. Duffy C., Lovell D., Assessment of Health
Status, Function, and Outcome, in Textbook of Pediatric Rheumatology, J.T.a.P.
Cassidy, Ross E, Editor. 2001, W.B. Saunders Company. p. 178-187.
70. Tucker LB, DeNardo BA, Abetz
LN et al.., The Childhood Arthritis
Health Profile (CAHP): validity and reliability of the condition specific
scales. Arthritis & Rheumatism, 1995. 38: p. S178.
71. Tucker LB, DeNardo BA, Schaller JG., The Childhood Arthritis Health
Profile: Correlation of juvenile rheumatoid arthritis specific scales with
disease severity and activity. Arthritis & Rheumatism, 1996. 39: p. S57.
72. Tucker LB., Outcome measures in childhood
rheumatic diseases. [Review] [32 refs]. Current Rheumatology Reports, 2000.
2(4): p. 349-54.
73. Lovell DJ, Howe S, Shear E,
et al., Development of a disability measurement tool for juvenile rheumatoid
arthritis. The Juvenile Arthritis Functional Assessment Scale. Arthritis &
Rheumatism, 1989. 32(11): p. 1390-5.